Financière de Tubize Reports 2026 Half-Year Profit of €100.8 Million, Increases UCB Stake to 36.29%
Key Takeaways
- •Financière de Tubize reported first-half 2026 net profit of €100.8 million, representing a 5.4% year-over-year increase from €95.6 million.
- •The company received €102.3 million in dividends from UCB SA, a 4.3% increase compared to the prior-year period.
- •Financière de Tubize acquired 15,783 additional UCB shares for €4.05 million, raising its ownership stake from 36.28% to 36.29% as of June 30, 2026.
- •The company paid €48.1 million in dividends to its own shareholders for 2025, equivalent to €1.08 per share and a 3.8% year-over-year increase.
- •Financière de Tubize's financial performance remains heavily dependent on UCB SA dividend distributions, reflecting its concentrated investment in the biopharmaceutical group.
August 1, 2026 — Regulated Information
The board of directors of Financière de Tubize has approved the company's 2026 half-year financial report. The full report is available on the company's official website at www.financiere-tubize.be.
Financière de Tubize is a Brussels-listed investment holding company whose principal asset is its substantial stake in UCB SA, the Belgian biopharmaceutical group focused on immunology and central nervous system therapies. The holding's financial results are therefore largely driven by UCB's dividend distributions, as reflected in the first-half figures.
Key Financial Highlights for the First Half of 2026:
- Net profit: €100.8 million, up 5.4% from €95.6 million in the same period of 2025.
- Dividend received from UCB: €102.3 million, corresponding to €1.45 per share, representing a 4.3% increase compared to the prior year.
- 2025 dividend paid to Financière de Tubize shareholders in 2026: €48.1 million, or €1.08 per share, reflecting a 3.8% year-over-year increase.
UCB Shareholding:
During 2026, Financière de Tubize acquired an additional 15,783 UCB shares for a total of €4.05 million at an average purchase price of €256.4 per share. As a result, the company's stake in UCB rose from 36.28% as of December 31, 2025, to 36.29% as of June 30, 2026. The incremental purchase continues a long-standing pattern of gradually increasing the holding's ownership position in UCB, reinforcing Financière de Tubize's role as the biopharmaceutical group's largest single shareholder.
